LONG MINI-FUTURE - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 18:43:11 28/06/2024 BST | ||
| 11.45 EUR | +1.42% |
|
| Current month | +24.32% | ||
| 1 month | +29.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 11.45 | +1.42% |
| 27/06/24 | 11.29 | +0.44% |
| 26/06/24 | 11.24 | +1.35% |
| 25/06/24 | 11.09 | -2.46% |
| 24/06/24 | 11.37 | +5.96% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 06:43 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM6W78 |
| ISIN | DE000VM6W787 |
| Date issued | 12/12/2023 |
| Strike | 355 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.41 € |
|---|---|
| Lowest since issue | 1.92 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
